When Did Ozempic Start Being Used for Weight Loss?

Last reviewed: June 29, 2026

Last updated: June 29, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide was originally developed to treat type 2 diabetes, but clinical observations in 2020–2021 revealed its powerful appetite-suppressing effects, sparking widespread off-label use for weight management. By 2023, demand had grown so dramatically that supply shortages affected both diabetic patients and those seeking weight loss. PlexusDx provides access to compounded semaglutide injection at $189/mo month-to-month, or from $149/mo on the 6-month plan, delivering the same active ingredient through licensed 503A pharmacies nationwide.

The Discovery of Semaglutide for Weight Loss

Semaglutide was approved by the FDA in 2008 as a once-weekly injectable treatment for type 2 diabetes under the brand name Ozempic. Researchers noticed that patients receiving the medication consistently lost weight as a secondary benefit, with some losing 10–15 pounds over several months of diabetes treatment. This observation planted the seed for investigating whether the drug could be repurposed specifically for weight management in non-diabetic individuals.

The turning point came when the STEP (Semaglutide Treatment Effect in People with obesity) clinical trials began enrolling participants in 2018. These landmark studies focused exclusively on obese adults without diabetes, measuring weight loss outcomes alongside metabolic markers. Results released between 2020 and 2021 showed that participants receiving semaglutide lost an average of 15–17% of their baseline body weight over 68 weeks—a result that grabbed attention from cardiologists, endocrinologists, and primary care physicians alike.

Off-Label Use and the 2021 Weight Loss Boom

Once STEP trial data became public in late 2020 and early 2021, doctors began prescribing Ozempic off-label for weight loss despite its diabetes-only FDA indication at the time. The off-label practice accelerated rapidly through 2021 and into 2022, driven by social media visibility, celebrity endorsements, and strong word-of-mouth within weight loss communities. Insurance companies initially covered these prescriptions sparingly, leaving most patients to pay out-of-pocket—a barrier that made compounded alternatives increasingly attractive.

The surge in demand created a perfect storm: supply chains couldn't keep up with prescriptions for both diabetic patients and weight loss seekers, leading to widespread shortages of brand-name Ozempic by late 2022. Pharmacies began rationing supplies, and some patients faced months-long waiting lists. This crisis pushed patients and providers toward compounded semaglutide, which is manufactured by licensed 503A pharmacies using the same FDA-grade active pharmaceutical ingredient.

FDA Approval of Wegovy and the Formal Weight Loss Era

The FDA formally approved semaglutide for chronic weight management under the brand name Wegovy in June 2021. Wegovy represented the first GLP-1 receptor agonist approved for weight loss in non-diabetic adults, validating what clinicians and patients had already observed in practice. The approval signaled a major shift in how the medical community viewed obesity—not as a lifestyle problem, but as a metabolic condition treatable with prescription medication.

Wegovy's approval came with a steep price tag: $1,300 per month at launch, with most insurance plans refusing coverage for weight loss indications. This cost barrier proved decisive in steering many patients toward compounded semaglutide through PlexusDx and similar providers. Compounded semaglutide injection costs $189 per month at PlexusDx's starting tier, making evidence-based GLP-1 therapy accessible to people who would otherwise be priced out of treatment.

How Modern Compounded Semaglutide Differs from Brand-Name Ozempic

Compounded semaglutide is manufactured by licensed 503A compounding pharmacies, which means it is individually prepared under strict FDA regulations rather than mass-manufactured on an assembly line. The active pharmaceutical ingredient is identical to brand-name Ozempic and Wegovy—both are semaglutide—but the delivery method and cost structure differ significantly. PlexusDx's compounded semaglutide injection provides the same dose escalation flexibility as brand products while eliminating the insurance-dependent pricing structure.

One key advantage of compounded formulations is price consistency: PlexusDx charges $189 per month flat regardless of your dose level. This pricing model ensures that dose increases needed over time do not trigger price hikes, addressing a major complaint from Wegovy patients who faced out-of-pocket costs climbing into the thousands. Additionally, compounded semaglutide is available in all 50 states without a membership fee, making it particularly accessible for patients in rural areas with limited pharmacy access.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Did Ozempic actually get approved for weight loss in 2021?

Ozempic itself was never approved for weight loss; it remains a diabetes medication. However, Wegovy—a brand name for semaglutide at higher doses—received FDA approval for chronic weight management in June 2021. Doctors had been prescribing Ozempic off-label for weight loss starting in 2021 based on STEP trial results, which is legal but technically not indicated.

What clinical evidence supports semaglutide for weight loss?

The STEP trials demonstrated that semaglutide reduced body weight by 15–17% over 68 weeks in obese adults, compared to 2–3% with placebo. These results were so robust that the FDA fast-tracked Wegovy's approval. Additionally, cardiovascular outcome trials showed that GLP-1 agonists reduce heart attack and stroke risk in patients with obesity and metabolic disease.

How much does compounded semaglutide cost at PlexusDx?

PlexusDx's compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan) and remains flat across all dose levels—your dose may increase, but your price won't. This is significantly cheaper than brand-name Wegovy, which often costs $900–$1,300 monthly with insurance or out-of-pocket. All medications are HSA/FSA eligible and available in all 50 states without insurance.

Are compounded semaglutide and Wegovy equally effective?

Yes—both contain the same active ingredient, semaglutide, so their weight loss and metabolic effects are equivalent when dosed identically. The main differences are manufacturing (compounded versus mass-produced), cost, and supply availability. Compounded semaglutide from licensed 503A pharmacies must meet the same purity and potency standards as brand products.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic
• Ozempic Weight Loss Before And After Pictures

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.